Delivery Order SPE2DB20D1110-SPE2DB25FJ74C

Award Date 11/5/24
Potential Completion Date 11/6/24
Potential Value $5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $36,630.61 firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award covers the delivery of the pharmaceutical product REXULTI 1 MG TABLET 30S, with a performance period through January 21, 2025. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This is a $2,820.09 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of the antipsychotic medication REXULTI 1 MG TABLET 30S. The order has a performance period ending on June 24, 2025. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle through...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The $2,654.22 firm fixed price delivery order is for the supply of REXULTI 2 MG TABLET 30S, with a period of performance through June 25, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a wide...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,550.23 firm fixed-price delivery order is for the supply of the prescription medication REXULTI 2 MG TABLET 30S. The contract has an ultimate completion date of December 18, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a firm fixed price delivery order contract worth $6,465.39 by the Defense Logistics Agency (DLA) to provide REXULTI 4 MG TABLET 30S, a pharmaceutical product. The contract has a completion date of March 8, 2024. This delivery order is issued under an existing indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA that has a potential value of up to $999,999,999.00 and a period of...
The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corporation, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract valued at $6,296.68 for the supply of REXULTI 0.5 MG TABLET 30S. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,378.84 firm fixed-price delivery order is for the supply of REXULTI 1 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of December 23, 2024 and was awarded on December 20, 2024. This award is a task order under AmerisourceBergen's $999,999,999 Indefinite Delivery Contract...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $7,962.66 firm fixed price delivery order is for the supply of REXULTI 2 MG TABLET 30S, a pharmaceutical product, with a period of performance through February 7, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA valued at up to $999,999,999.00 through December 31, 2025. This IDC...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $6,366.17, is a Firm Fixed Price Delivery Order to supply the pharmaceutical product REXULTI 0.5 MG TABLET 30S. The contract has an ultimate completion date of February 10, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution company. The contract, valued at $8,633.19, is for the delivery of the pharmaceutical product REXULTI 2 MG TABLET 30S. The contract has an ultimate completion date of April 3, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA,...
  • SPE2DB20D1110
    Indefinite Delivery Contract
  • SPE2DB20D1110-SPE2DB25FJ74C
    Delivery Order

This is a $4,954.98 firm fixed-price delivery order awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) for the supply of pharmaceutical product REXULTI 2 MG TABLET 30S. The award has an ultimate completion date of November 6, 2024. Amerisourcebergen is a for-profit pharmaceutical distribution and healthcare solutions provider that holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, as well as a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation, both of which cover the provision of various pharmaceutical and medical products to support federal healthcare programs. This specific award does not have a set-aside designation, indicating open competition.

Generated 2/4/25, 10:31 AM